Clinical Trial Update: The Aim of This Study is to Compare the Efficacy of Perioperative Hypertonic Saline 3% Versus Normal Saline (0.9%) in Decreasing Recurrence Risk in Non-muscle Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing perioperative hypertonic saline 3% to normal saline for reducing recurrence risk in non-muscle invasive bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Hypertonic saline 3% (sodium chloride 3% solution)
• Normal saline 0.9% (sodium chloride 0.9%)

Snippet

Sponsor: Kaplan Medical Center | Conditions: TCC | Phase 2 | Status: UNKNOWN